A phase I/IIa trial is designed to study the combination of rigosertib plus nivolumab (an immune checkpoint inhibitor) in metastatic KRAS+ lung adenocarcinoma adult patients who have progressed on standard first-line treatment (NCT04263090). The gene discussed is KRAS; the disease is lung adenocarcinoma.